fda glp-1 warning november 2025 Receptor Agonists and vision risk FDA unleashes warning letters to

Nirvanix Health

Some people need a slower titration, a lower maintenance dose, or a different medication altogether

Increasing attention has been directed toward the concept of a therapeutic window of opportunity, which frames early PsA as a transitional phase characterized by musculoskeletal symptoms such as arthralgia, dactylitis, and subclinical enthesitis in patients with PsO, often preceding clinically evident arthritis ( These considerations highlight the need for future studies specifically designed to evaluate GLP-1RAs in patients at high risk of PsA, particularly those with subclinical inflammation or early musculoskeletal symptoms

Youre dehydrated: Delayed gastric emptying means you feel satisfied with less food, which can lead to reduced eating and drinking